Home › Funds › Kepler Cheuvreux (Suisse) SA › RPRX
Kepler Cheuvreux (Suisse) SA position in RPRX
ROYALTY PHARMA PLC · Health Care
Kepler Cheuvreux (Suisse) SA reported holding 391,457 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$22.8M, representing 1.39% of its reported portfolio and ranking #25 among its reported holdings. Kepler Cheuvreux (Suisse) SA has disclosed RPRX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-10-20 · Source: SEC EDGAR Form 13F-HR
How Kepler Cheuvreux (Suisse) SA's RPRX position evolved
Kepler Cheuvreux (Suisse) SA first disclosed a stake in RPRX in Q2 2026 at 160,345 shares (US$9.0M). The position peaked in Q3 2026 at 391,457 shares, worth US$22.8M. Across 2 filings, Kepler Cheuvreux (Suisse) SA increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 391,457 shares valued at US$22.8M — an increase of 231,112 shares quarter over quarter.. Notable position changes include a 144% increase in Q3 2026 (shares rose 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 160.34K | $8.99M | New |
| Q3 2026 | 391.46K | $22.85M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RPRX and 13F data
RPRX (ROYALTY PHARMA PLC) is a Health Care company. 50 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$601.4M), Baillie Gifford & Co (US$561.6M), Caledonia (Private) Investments Pty Ltd (US$323.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RPRX
- Swedbank AB 10.73M sh · $601.44M · Q2 2026
- Baillie Gifford & Co 10.02M sh · $561.57M · Q2 2026
- Caledonia (Private) Investments Pty Ltd 5.78M sh · $323.85M · Q2 2026
- ROYAL LONDON ASSET MANAGEMENT LTD 4.32M sh · $242.20M · Q2 2026
- Patient Capital Management, LLC 3.60M sh · $201.79M · Q2 2026
- Dorsey Asset Management, LLC 2.46M sh · $137.74M · Q2 2026
- Regal Partners Ltd 2.45M sh · $137.25M · Q2 2026
- NEW SOUTH CAPITAL MANAGEMENT INC 2.39M sh · $133.78M · Q2 2026
- Clark Capital Management Group, Inc. 1.66M sh · $93.24M · Q2 2026
- HOMESTEAD ADVISERS CORP 1.66M sh · $92.92M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.38M sh · $77.67M · Q2 2026
More on Kepler Cheuvreux (Suisse) SA
FAQ
How long has Kepler Cheuvreux (Suisse) SA held RPRX?
Kepler Cheuvreux (Suisse) SA has disclosed RPRX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Kepler Cheuvreux (Suisse) SA's current position in RPRX?
As of Q3 2026, Kepler Cheuvreux (Suisse) SA holds 391.46K shares of RPRX (ROYALTY PHARMA PLC), valued at $22.85M, representing 1.39% of its reported portfolio and ranking #25.
Has Kepler Cheuvreux (Suisse) SA been buying or selling RPRX?
In the latest 13F filing (Q3 2026), Kepler Cheuvreux (Suisse) SA increased its position in RPRX. The position peaked in Q3 2026 at 391.46K shares.
Which other funds hold RPRX?
Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, Caledonia (Private) Investments Pty Ltd, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.